NeoPharm (NEOL) Announces Efficacy Results For Phase 3 PRECISE Trial; Drug Misses Goal In Brain-Cancer Trial; Stock Plunges
WAUKEGAN, Ill.--(BUSINESS WIRE)--NEOPHARM, Inc. (Nasdaq: NEOL - News) today announced that the pivotal Phase 3 PRECISE trial evaluating cintredekin besudotox (IL13-PE38QQR) for the treatment of recurrent glioblastoma multiforme (GBM) did not meet the efficacy endpoint at 215 deaths, which was a statistically significant difference, or separation, in the overall survival curves versus Gliadel Wafer®. "Topline data suggests that cintredekin besudotox, while comparable, was not statistically superior to Gliadel," said Guillermo A. Herrera, President and Chief Executive Officer of NEOPHARM. "We will continue to work with our Scientific Advisory Board and the FDA to determine the best path forward."
Median Survival CB = 36.4 weeks
Median Survival Gliadel = 35.3 weeks
Damn! You take a slice of the population that has 9 months to live and you try to make a profit by extending the worst year of their life. There has got to be some chemical out there that can make this happen.
Good riddance NeoPharm.
No comments:
Post a Comment